Breakthrough Therapies for Autoimmune Diseases and Cancer
Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies targeting KLRG1 (Killer cell Lectin-like Receptor G1) for rare autoimmune diseases and cancers. Its lead candidate ulviprubart (ABC008) is in Phase 2/3 pivotal trials for Inclusion Body Myositis (IBM) and Phase 1 trials for T-Cell Large Granular Lymphocytic Leukemia (T-LGLL). The company has raised over $200M in Series C financing led by New Enterprise Associates with participation from Sanofi Ventures, RA Capital, and Bain Capital Life Sciences.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2025
Aug 2023
Jan 2021
Jan 2018
Dec 2016
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
